Xbrane has released the company's 2023 Annual and Sustainability Report. The report summarises business, financial performance and work on sustainability.

”2023 provided both ups and downs. We entered a commercial phase with the European launch of Ximluci®, but sales have not met expectations. We have made the necessary structural changes, and provided that we reach the next milestones, 2024 will be a pivotal year for Xbrane” says Martin Åmark CEO.

Xbrane Biopharma AB’s annual report for 2023 is now available at the company’s website, www.xbrane.com.
The annual report includes the corporate governance report and the sustainability report for 2023.
The Report is distributed to the shareholders and others that made such request. It can also be ordered from Xbrane Biopharma on the following address:

Xbrane Biopharma AB
Retzius väg 8
171 65 Solna
Sweden
Or via e-mail: ir@xbrane.com

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com  

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-03-27 17:15 CET.

Attachments

Annual And Sustainability Report 2023 Xbrane Biopharma AB
Xbrane Biopharma ESEF rapportering 2023

© Modular Finance, source Nordic Press Releases